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Background: Fewer Canadian seniors are vaccinated against pneumococcal disease than receive the influenza
vaccine annually. Improved understanding of factors influencing pneumococcal vaccination among older adults is
needed to improve vaccine uptake.
Methods: A self-administered survey measuring knowledge, attitudes, beliefs and behaviours about pneumococcal
vaccination was administered to a cohort of seniors participating in a clinical trial of seasonal influenza vaccines at
eight centers across Canada. Eligible participants were ambulatory adults 65 years of age or older, in good health or
with stable health conditions, previously given influenza vaccine. The primary outcome was self-reported receipt of
pneumococcal vaccination. Multi-variable logistic regression was used to determine factors significantly associated
with pneumococcal vaccine receipt.
Results: A total of 863 participants completed questionnaires (response rate 92%); 58% indicated they had received
the pneumococcal vaccine. Being offered the vaccine by a health care provider had the strongest relationship with
vaccine receipt (AOR 23.4 (95% CI 13.4-40.7)). Other variables that remained significantly associated with vaccine
receipt in the multivariable model included having heard of the vaccine (AOR 10.1(95% CI 4.7-21.7)), and strongly
agreeing that it is important for adults > 65 to be vaccinated against pneumococcus (AOR 3.3 (95% CI 1.2-9.2)).
Participants who were < 70 years of age were less likely to be vaccinated.
Conclusions: These results indicate healthcare recommendation significantly influenced vaccine uptake in this
population of older adults. Measures to encourage healthcare providers to offer the vaccine may help increase
coverage.
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Invasive pneumococcal disease (IPD), caused by the
Streptococcus pneumoniae bacterium, frequently results
in serious outcomes including bacteremia, meningitis,
bacterial pneumonia and death; vaccination is the pri-
mary means of prevention. In 2010, the incidence of IPD
among adults 60 years of age and older in Canada was
23.2 per 100,000 and accounted for 48% of IPD cases re-
ported in the country [1]. Vaccination coverage against
pneumococcal disease is consistently lower than cover-
age for seasonal influenza among the elderly population
in Canada and globally [2]. The most recent data avail-
able from the 2006 Canadian National Immunization
Coverage Survey, based on self-report of vaccination sta-
tus, estimated that only 39% of individuals 65 years of
age and older had ever been vaccinated against pneumo-
coccal disease whereas 70% had received the influenza
vaccine that season [3]. A 2007 systematic review of the
determinants of influenza and pneumococcal vaccination
in the elderly, which included 14 studies from around
the world, not including Canada, found the strongest
predictors of pneumococcal vaccination were older age
and physician recommendation [2]. Canadian studies of
the knowledge and determinants of pneumococcal vac-
cination in older adults are lacking.
Currently, the polysaccharide pneumococcal vaccine
(PPS), which covers 23 pneumococcal serotypes, is rec-
ommended and publicly funded for all adults 65 years of
age and older in Canada [4] and in January 2012 the 13-
valent pneumococcal conjugate vaccine was approved
for use among adults over 50 years of age in Canada.
The conjugate vaccine is made from purified polysaccha-
rides of 13 different serotypes of S. pneumonia individu-
ally conjugated to non-toxic diphtheria cross reactive
material 197 (CRM197) protein [5]. At the current time,
the 13 valent conjugate vaccine is recommended and
funded for Canadian infants and in some jurisdictions
for adults with specific health conditions that place them
at increased risk for pneumococcal infection (e.g. immuno-
compromised) [6]. Because pneumococcal immunization
coverage rates remain low and newer conjugate vaccines
may improve vaccine performance [7], the objective of this
study was to understand the knowledge, attitudes and be-
liefs of an older population regarding pneumococcal
immunization. An improved understanding of the factors
influencing pneumococcal vaccine uptake among older
adults could allow development of targeted interventions
to promote pneumococcal immunization in hopes of im-
proving vaccine coverage in this higher-risk age group.
Methods
A cross-sectional survey was given to a convenience
sample of adults participating in a clinical trial of seasonal
influenza vaccines conducted by PCIRN (the PublicHealth Agency of Canada/Canadian Institutes of Health
Research Influenza Research Network, http://pcirn.ca)
between October 6 and November 17, 2011. Eligible par-
ticipants were English or French speaking ambulatory
adults 65 years of age or older, in good health or with
stable health conditions, who had received the influenza
vaccine within the past two years. Further, all participants
lived independently or in centers providing minimal
support for daily living activities. Recruitment occurred
in health centers in five Canadian provinces (British
Columbia, Manitoba, Ontario, Quebec and Nova Scotia).
The study was approved by the following research ethics
boards: University of Manitoba Bannatyne Research Ethics
Board, McGill University Health Centre Biomedical
Department Research Ethics Board, Hamilton Health
Sciences McMaster University Research Ethics Board,
IWK Research Ethics Board, Mount Sinai Hospital Research
Ethics Board, Ottawa Hospital Research Ethics Board,
Centre Hospitalier Universitaire de Quèbec comitè d’èthi-
que, and the University of British Columbia, Children’s &
Women’s Health Centre of BC Research Ethics Board.
Participants were not provided with an incentive to
complete the survey and all participants provided writ-
ten informed consent.
Survey instrument
The self-administered questionnaire (supplemental in-
formation online) was based on the theory of planned
behaviour [8] and the health belief model [9] and con-
sisted of 25 questions. It measured the subject’s knowledge
of pneumococcal infection and immunization (three ques-
tions), perceived risk (three questions), personal normative
beliefs (three questions), attitudes towards vaccines (six
questions), facilitating conditions for vaccination (three
questions) and respondent characteristics (7 questions).
Of the 25 questions, ten were on a six point Likert scale
with options of: “strongly disagree”, “somewhat disagree”,
“neither agree nor disagree”, “somewhat agree”, “strongly
agree” and “I don’t know”, eight questions had the option
of “yes”, “no” or “I don’t know” and seven questions tar-
geted demographics. Demographic information collected
included sex, age, ethnicity, education level, hospitalization/
emergency department/walk in clinic visit in the last year,
vaccination status, and approximate annual household in-
come. A measure of frailty was assigned to each partici-
pant by a site investigator (nurse or physician) using the
previously validated Canadian Study of Health and Aging
Clinical Frailty Scale which is a seven point scale ranging
from “very fit” to “severely frail” [10]. The survey instru-
ment, which was previously used in a younger population
of parents and pregnant women, was pilot tested on the
first ten participants at each centre to ensure clarity and
comprehension; however, validity and reliability were not
measured. All data collected were used in the analysis.
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questionnaires for completeness and were available to
offer participant clarification. If participants had questions
regarding pneumococcal disease or the vaccine, these
were addressed after the survey was completed and a
pneumococcal information pamphlet was made available
to all participants (supplemental information).Outcome measure
The outcome variable used was self-reported receipt of
the pneumococcal vaccine. All study participants were
asked, “Have you ever previously had the pneumonia
vaccine?” Possible responses were, “yes”, “no” or “I don’t
know”. Individuals indicating unknown vaccination sta-
tus (n = 75, 8.75%) were excluded from the regression
models. These individuals were older (29.3% > 80 years)
and a larger proportion were “apparently vulnerable”
(6.7%) relative to individuals who remembered their vac-
cination status, otherwise they were similar to the rest of
the study participants.Statistical analysis
Data analysis was performed using SAS version 9.3 for
Windows (SAS Institute Inc., Cary, NC). All variables
were explored descriptively with frequencies. Due to lack
of dispersion across categories, all questions on the six
point Likert scale were collapsed to four categories for
the purpose of model building: “strongly agree”, “some-
what agree”, “strongly or somewhat disagree” and “I
don’t know” (a combination of those who responded
“neither agree nor disagree” and “I don’t know”). Bi-variable
analyses investigating the relationships between self-
reported vaccination status and all survey questions in-
cluding demographics, knowledge, attitudes and beliefs
variables were performed using Pearson’s chi-square
test and logistic regression.
A multi-variable logistical regression model was built
to identify the variables that were associated with self-
reported vaccination status. All survey variables with a
significant crude relationship with vaccination status,
with the exception of those identified as being collinear
and those lacking the dispersion required, were included
in the initial model. Demographic variables were in-
cluded as potential confounders. A backward elimination
process was used (alpha >0.10) to determine the best
predictive model, this model was robust to stepwise and
forward selection model building processes. The variable
“centre”, which represented the recruitment health centre,
was retained in the model to account for similarities in
the outcome status between individuals from the same
centre. Model fit was assessed by examining the results of
the Hosmer and Lemeshow goodness-of fit test and the
Deviance residuals.Results
Study population
Participant demographic characteristics by vaccination
status are shown in Table 1. Of the 937 eligible individuals
(59.3% female), 863 completed questionnaires (response
rate 92%). The mean age of participants was 73.6 years
with significantly more women participating than men
(59%, p < 0.01). Almost all (98%) indicated they had a
regular doctor for primary care whom they had visited in
the last year (96%).
Seventy-one percent (n = 615) of participants stated
they had heard of a vaccine that prevents pneumonia. Of
those who had heard of the vaccine, 26% (n = 157) had
not been told about it by their doctor/healthcare pro-
vider. Results from the knowledge, attitudes and beliefs
questions can be found in Tables 2 and 3.
The percentage of individuals who self-identified as
being in a high risk group for pneumonia varied with
frailty score. Thirty seven percent of individuals who
were “very fit”, 40.2% who were “well”, 45.3% who
were “well with treated co-morbid disease” and 43.5%
of those who were “apparently vulnerable” either
strongly or somewhat agreed with the statement “I am
at high risk of pneumonia”; 21.5%, 19.9%, 13.2% and
17.4% of the “very fit”, “well”, “well, with treated co-
morbid disease” and “apparently vulnerable” respect-
ively either somewhat or strongly disagreed with the
same statement.Vaccination status and bi-variable analyses
Fifty eight percent of participants (n = 502) indicated
they had previously received the pneumonia vaccine.
Those with higher unadjusted odds of vaccination in-
cluded: women, individuals 70–79 years old, those with
less than a university education, and individuals who
were well with treated co-morbid disease relative to
those who were well or very fit. Further, having been of-
fered the pneumococcal vaccine by a health care pro-
vider, having been told by a healthcare provider about
the pneumonia vaccine and believing their healthcare
provider thought receipt of the vaccine was a good idea
were all positively associated with vaccine receipt. As
these latter three variables were highly correlated, recal-
ling having been offered the vaccine by a health care
provider was chosen for use in the multi-variable
models as it was the strongest predictor of vaccination
status. There was variation in distribution of vaccin-
ation status by study site. Montreal had the highest per-
centage of participants who reported receipt of the
pneumonia vaccine (75%), 10% greater than any other
study site. The majority of knowledge and attitude ques-
tions had a significant crude relationship with vaccin-
ation status (Tables 2 and 3).






n % n %
Sex Male 354 41.0 176 49.7
Female 509 59.0 326 64.0
Age category 65- < 70 303 35.1 138 45.5
70- < 80 407 47.2 272 66.8






282 32.8 177 62.8
College 185 21.5 114 61.6
University 369 42.9 195 52.8
Other 15 1.7 9 60
Prefer not to answer 10 1.2 5 50
Household income < $35,000 178 20.8 110 61.8
$35,000 to $75,000 323 37.7 199 61.6
Over $75,000 173 20.2 89 51.5
Prefer not to answer 182 21.3 100 55.0
Ethnicity White/Caucasian 820 95.0 475 57.9
Asian 29 3.4 20 69.0
Other 14 1.6 7 50.0
Frailty Very fit 349 40.4 195 55.9
Well 309 35.8 176 57.0
Well, with treated
co-morbid disease
177 20.5 116 65.5
Apparently
Vulnerable/Mildly frail
28 3.2 15 53.6
Centre Ottawa 43 5.0 16 37.2
Halifax 161 18.7 92 57.1
Hamilton 33 3.8 9 27.3
Montreal 155 18.0 117 75.5
Winnipeg 101 11.7 66 65.4
Vancouver 118 13.7 73 61.9
Toronto 147 17.0 60 40.8
Quebec City 105 12.2 69 65.7
*Number and percent of vaccinated individuals within each category.
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Variables significantly associated with receipt of vaccine
in the multivariable logistic regression model are shownin Table 4. Being offered the vaccine by a health care
provider had the strongest relationship with vaccine re-
ceipt. Other variables that remained in the multivariable
model included having heard of the vaccine, and
strongly agreeing that it is important for adults older
than 65 years to be vaccinated and age category.
Discussion
Fifty-eight percent of study participants recalled receiving
the pneumococcal vaccine, a result that is 20% higher than
the findings of the 2006 National Immunization Coverage
Survey (NICS) which found only 39% of Canadians ≥ 65 years
of age recalled being immunized against pneumococcal
disease [3]. This could reflect a true increased coverage
among older adults in Canada, or it could be reflective of
differences in our study population, which was highly
compliant with annual influenza vaccination. In 2006, the
national target for pneumococcal vaccine coverage was
80% among older adults. Although our results are still well
below this level, the data suggest an increasing trend.
Vaccine provision by a healthcare provider is consist-
ently found to be one of the strongest independent pre-
dictors of pneumococcal and influenza vaccine receipt
among the elderly [11-14], a finding reproduced in this
study. Although most participants had access to a health
care provider (97% had seen their primary care provider
in the past year), and therefore the opportunity to be of-
fered the vaccine, only 52% remembered their health
care provider offering them the pneumococcal vaccine
at any time. This is important as approximately 9 out of
10 participants who indicated they had been offered the
pneumococcal vaccine by a healthcare provider in the
past also remembered being vaccinated compared to 3
out of 10 participants who did not recall being offered
the vaccine by a healthcare provider. Healthcare pro-
viders should routinely offer to immunize their older pa-
tients with the pneumococcal vaccine. They have an
essential role in educating their patients about the risks
of IPD. In a recent meta-analysis, clinician reminders
and education and patient outreach involving personal
contact were all identified as factors that have been ob-
served to improve coverage of pneumococcal vaccination
among community dwelling adults [15].
Uncertainty about the effectiveness of pneumococcal
vaccines among physicians may help to explain the ap-
parent lack of advocacy for immunization. Some clinical
trials and recent large observational studies have found
that the polysaccharide vaccine is associated with re-
duced risk of pneumococcal bacteremia, presumptive
pneumococcal pneumonia and both pneumococcal and
all-cause community acquired pneumonia [16-19] how-
ever, a meta-analysis of clinical trials investigating the effi-
cacy of PPS in adults found higher quality trials failed to
find a protective effect [16]. A recent nested case–control














% (n) % (n) % (n) % (n) % (n) % (n)
Knowledge
The pneumonia vaccine keeps a person
from getting pneumonia*
Vaccinated 57.6 (288) 31.2 (156) 4.4 (22) 1.0 (5) 1.0 (5) 4.8 (24)
Unvaccinated 30.4 (87) 33.2 (95) 8.4 (24) 1.4 (4) 0 26.6 (76)
Perceived risk
Pneumonia is a serious disease*
Vaccinated 91.4 (459) 6.8 (34) 0.6 (3) 0 0 1.2 (6)
Unvaccinated 83.2 (238) 14.0 (4) 0.4 (1) 0.7 (2) 0 1.8 (5)
I am at high risk for pneumonia*
Vaccinated 18.9 (95) 25.9 (130) 20.3 (102) 10.2 (51) 7.6 (38) 17.1 (86)
Unvaccinated 8.4 (24) 24.4 (67) 22.7 (65) 12.2 (35) 9.4 (27) 23.8 (68)
A person who does NOT get the pneumonia
vaccine will probably get pneumonia*
Vaccinated 5.5 (27) 13.9 (69) 39.8 (197) 0 0.2 (1) 0.4 (2)
Unvaccinated 2.8 (8) 10.1 (29) 24.8 (71) 0.7 (2) 0.4 (1) 1.4 (4)
Normative
My doctor’s/health care provider’s recommendations
are important
Vaccinated 89.0 (445) 9.4 (47) 0.6 (3) 0.2 (1) 0.2 (1) 0.6 (3)
Unvaccinated 84.6 (241) 13.0 (37) 1.8 (5) 0 0 0.7 (2)
Attitudes
In general, vaccines are a good way to
protect my heath*
Vaccinated 93.2 (466) (5.4) 27 0.8 (4) 0.2 (1) 0.2 (1) 0.4 (2)
Unvaccinated 83.6 (239) 12.9 (37) 101 (3) 0.7 (2) 0 1.8 (5)
I consider vaccines to be safe*
Vaccinated 75.6 (378) 21.6 (108) 2.0 (10) 0 0.2 (1) 0.6 (3)
Unvaccinated 65.3 (186) 30.9 (88) 1.4 (4) 1.8 (5) 0 9.8 (28)
I feel that getting the pneumonia vaccine
is a wise thing to do*
Vaccinated 92.0 (460) 6.0 (30) 1.2 (6) 0.2 (1) 0.2 (1) 1.4 (7)
Unvaccinated 52.5 (150) 27.6 (79) 8.4 (24) 2.1 (6) 0.7 (2) 9.4 (27)
It is important for healthy adults over the age
of 65 to get the pneumonia vaccine*
Vaccinated 90.4 (452) 7.2 (36) 0.6 (3) 16.8 (83) 5.7 (28) 18.4 (91)
Unvaccinated 47.6 (136) 29.0 (83) 11.2 (32) 23.8 (68) 18.5 (53) 19.9 (57)
I consider the pneumonia vaccine to be safe*
Vaccinated 76.4 (379) 18.6 (92) 2.0 (10) 0.2 (1) 0.4 (2) 2.4 (12)
Unvaccinated 40.6 (116) 25.9 (74) 11.5 (33) 1.1 (3) 0 21.0 (60)
*Questions where p < 0.05 for Pearson’s chi square test of the null hypothesis that there is no association between vaccination status and categorical response to
question (based on the 4 collapsed categories as described in methods).
**Does not include responses from individuals who indicated they “Did not know” their vaccination status (n = 75).
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Table 3 Distribution of responses to knowledge, beliefs and facilitating conditions questions by vaccination status
Yes No I don't know
% (n) % (n) % (n)
Knowledge
I have heard about a vaccine that prevents pneumonia*
Vaccinated 90 (452) 3.8 (19) 6.2 (31)
Unvaccinated 44.8 (128) 46.5 (133) 8.7 (25)
The pneumonia vaccine is the same as the flu vaccine*
Vaccinated 5.3 (26) 74.9 (369) 19.9 (98)
Unvaccinated 5.2 (15) 53.9 (154) 40.9 (117)
Normative
My doctor/health care provider told me about the pneumonia vaccine*
Vaccinated 79.8 (396) 16.7 (83) 3.4 (17)
Unvaccinated 18.2 (52) 76.6 (219) 5.2 (15)
My doctor/health care provider thinks I should get the pneumonia vaccine*
Vaccinated 77.8 (381) 7.6 (37) 14.7 (72)
Unvaccinated 14.7 (42) 23.8 (68) 61.5 (176)
My doctor/health care provider has offered me the pneumonia vaccine*
Vaccinated 80.2 (397) 17.8 (88) 2 (10)
Unvaccinated 11.5 (33) 82.1 (235) 6.3 (18)
Attitudes
It is important to use vaccines to prevent disease like pneumonia*
Vaccinated 95.4 (472) 1 (5) 3.6 (18)
Unvaccinated 84.2 (240) 1.4 (4) 14.4 (41)
Facilitating conditions
I have a regular doctor for primary care
Vaccinated 98.8 (495) 1.2 (6) NA
Unvaccinated 98.6 (282) 1.4 (4) NA
I have visited my primary health care provider in the last year
Vaccinated 97.4 (487) 2.6 (13) NA
Unvaccinated 96.1 (274) 3.9 (11) NA
I have been to a hospital, emergency department or walk in clinic in the last year
Vaccinated 33.7 (92) 66.3 (181) NA
Unvaccinated 38 (192) 62 (313) NA
*Questions where p < 0.05 for Pearson’s chi square test of the null hypothesis that there is no association between vaccination status and categorical response to question.
**Does not include responses from individuals who indicated they “Did not know” their vaccination status (n = 75).
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males compared to males (68% vs. 34% respectively) [20].
These conflicting results make it difficult to determine the
true efficacy of the vaccine. It is possible, that if strong evi-
dence of improved performance of the conjugate vaccine
relative to PPS in adult populations is found, clinicians
may be more motivated to provide recommendations to
their adult patients. Other barriers to physicians immuniz-
ing with PPS that have been previously identified include
other urgent concerns dominating office visits, rarity
of pneumonia in their daily practice, not being able todetermine vaccine status and lack of knowledge regarding
the possibility of revaccination [21-23].
Consistent with previous findings from the United
States [14], Spain [24] and Sweden [25], individuals
70 years of age or older had a significantly higher prob-
ability of having been vaccinated relative to participants
less than 70 years of age. Also consistent with previous
findings, participants who were “well, with treated co-
morbidities” had a higher probability of vaccine receipt
relative to those who were deemed “very fit” on the
frailty scale [25,26]. This observation may be partially
Table 4 Variables associated with self-reported pneumococcal vaccination status in multivariable analysisa, b
Unadjusted OR 95% CI Adjusted OR 95% CI
I have heard about a vaccine that prevents pneumonia
No Reference Reference
Don’t know 8.68 4.25 17.71 3.25 1.06 9.93
Yes 24.71 14.7 41.53 10.14 4.74 21.68
The pneumonia vaccine is the same as the flu vaccine
Yes Reference Reference
Don’t know 0.48 0.24 0.96 1.36 0.45 4.18
No 1.38 0.71 2.68 2.75 0.94 8.01
My doctor/health care provider has offered me the pneumonia vaccine
No Reference Reference
Don’t know 1.48 0.66 3.34 1.37 0.49 3.84
Yes 32.13 20.87 49.45 23.38 13.44 40.69
It is important for healthy adults over the age of 65 to
get the pneumonia vaccine
I don’t know Reference Reference
Strongly agree 19.61 9.77 39.37 3.33 1.2 9.2
Somewhat agree 2.56 1.18 5.56 0.88 0.28 2.77
Somewhat/Strong disagree 1.48 0.27 7.98 1.08 0.08 15.55
Education
University Reference Reference
College/Other 1.33 0.92 1.92 0.78 0.41 1.46
Primary/secondary 1.6 1.13 2.25 1.49 0.82 2.72
Frailty
Very Fit Reference Reference
Well 1.22 0.88 1.69 1.59 0.9 2.81
Well, with treated co-morbid disease 1.87 1.24 2.82 1.96 0.94 4.09
Apparently vulnerable 1.3 0.54 3.15 1.77 0.31 9.95
Age
65- < 70 Reference Reference
70- < 80 2.67 1.93 3.69 4.02 2.3 7.03
80 + 2.43 1.56 3.78 3.67 1.66 8.12
aexcludes participants who indicated “I don’t know” to having received the pneumococcal vaccine (n = 75) and with those with missing data for explanatory
variables (n = 35).
bCentre is in model to adjust for similarities between participants from the same centre.
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tion. Individuals who were deemed “very fit” or “well”
were significantly more likely to strongly or somewhat
disagree to the statement “I am at high risk for pneumonia”
relative to those who were deemed “well, with treated-
co-morbid disease” or “apparently vulnerable” (20.2% vs
12.2%). A 2007 meta-analysis of the relationship be-
tween risk perception and vaccination behaviour among
adults found that an individual’s perceptions of risk, and
perceived severity of the disease are both associated
with vaccination behaviour [27]. This suggests that one
area of intervention to increase vaccine uptake could in-
clude education programs for individuals in their late60’s and who are apparently healthy, which focus on
their heightened risk of IPD and their risk of more se-
vere outcomes due to their age.
Increasing awareness about pneumococcal vaccines
and the risk of infection among older adults is needed as
it has been found that not being vaccinated with PPS is
directly associated with a lack of knowledge about the
vaccine among adults 65 years of age of older [14]. We
found that having heard of the vaccine and knowing that
the pneumococcal vaccine was different than the influ-
enza vaccine were associated with a higher probability of
recalling vaccination. Although not surprising, these
findings are an important reminder that the older adult
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regarding the availability of vaccinations that can be
accessed to maintain good health. Among the vaccine-
accepting population recruited for this study, 20% indi-
cated they had not heard of the pneumococcal vaccine
despite all participants being eligible to receive the vaccine
free of charge. The proportion of individuals lacking
knowledge of the vaccine is likely higher among the gen-
eral older adult population of Canada.
Because a recommendation from a healthcare provider
is the strongest predictor of vaccination, information on
the pneumococcal vaccine would likely be well-received
from such a source and healthcare providers will be the
key source for most people. However, other sources of
communication may also be important. Approximately
26% of participants in our study who had heard of the
pneumococcal vaccine said their healthcare provider did
not tell them about it or offer it to them, indicating that
these participants accessed their information differently.
Of interest is the developing role of pharmacists in pro-
viding vaccinations in Canada. Pharmacists are, or will
soon be licensed to vaccinate in six provinces and are
another potential route of informing the population about
the vaccines recommended and available to them [28].
Individuals participating in this study had a history of
vaccination, since they had all received an influenza vac-
cine in the prior two years. They were ambulatory adults
65 years of age or older, in good health or with stable
health conditions. With this in mind, these results may
not be generalizable to all older adults in Canada. Even
in this highly motivated population, the uptake was
lower than the national target indicating room for im-
provement. The outcomes of vaccination status, and
having been offered the pneumococcal vaccine by a
health care provider were both based on self-report and
thus subject to recall bias. Finally, this is an analysis of
cross-sectional data so it is not possible to determine
temporality. It is not clear if participants heard of the
vaccine because they were vaccinated or were vaccinated
because they had heard of the vaccine. Although tem-
porality cannot be established, it remains valuable to
consider the strongest relationships identified and the
role these variables may play in increasing vaccination
against IPD.
Conclusions
Coverage with PPS among older adults in Canada remains
low. The results of this study indicate that investing re-
sources to educate healthy seniors about their risk of IPD
could increase coverage with PPS. The largest gains in
coverage would likely be achieved through improved
education of patients and physicians as well as recom-
mendations to vaccinate, and provision of vaccine by
health care providers.Competing interests
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